Citations

Point of Care Testing of Fecal Calprotectin as a Substitute for Routine Laboratory Analysis

January 30, 2018
BÜHLMANN fCAL® turbo and IBDoc®: Hejla, J, Theedeb, K, et al.  Point of care testing of fecal calprotectin as a substitute for routine laboratory analysis.  Practical Laboratory Medicine; 10 (2018) 10-14. PMID: 29234707 DOI: 10.1016/j.plabm.2017.11.002 Highlights from this Publication “This study suggests that IBDoc® is a suitable alternative for the assessment of disease activity in IBD patients. Point of care
Read more

Fecal Calprotectin Measurement is a Marker of Short-Term Clinical Outcome and Presence of Mucosal Healing in Patients with Inflammatory Bowel Disease

December 19, 2017
BÜHLMANN fCAL® ELISA: A.Kostas, et al. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease. World Journal of Gastroenterology; November 2017. PMID: 29151692 DOI: 10.3748/wjg.v23.i41.7387. Highlights from this Publication “In our patient cohort, we were able to define an optimal cut-off FC value of 261 µg/g, which had a strong
Read more

Quantum Blue® Adalimumab: Development of the first point of care rapid test for therapeutic drug monitoring of serum adalimumab levels

October 10, 2017
Quantum Blue® Infliximab Citation: F. I. Bantleon, S. Kräuchi, T. B. Schuster, M. Schneider, A. P. Abel Read Citation
Read more

The new infliximab point-of-care quantitative test can equally be used for therapeutic drug monitoring of biosimilars of infliximab

October 10, 2017
Quantum Blue® Infliximab Citation: J. Afonso, H.T. Sousa, I.Rosa, J.Carvalho, C. C. Dias, F. Magro on behalf GEDII Read Citation
Read more